Innate Pharma S.A. (IPHA)

Market Cap	130.95M -22.8%
Revenue (ttm)	10.57M -55.2%
Net Income	-57.74M
EPS	-0.65
Shares Out	92.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,877
Open	1.440
Previous Close	1.450
Day's Range	1.420 - 1.450
52-Week Range	1.170 - 2.630
Beta	0.75
Analysts	Strong Buy
Price Target	5.75 (+300.47%)
Earnings Date	Mar 26, 2026

About IPHA

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 17, 2019
• Employees: 163
• Stock Exchange: NASDAQ
• Ticker Symbol: IPHA
• Website: https://www.innate-pharma.com

Financial Performance

In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.

Financial numbers in EUR

Analyst Summary

According to 4 analysts, the average rating for IPHA stock is "Strong Buy." The 12-month stock price target is $5.75, which is an increase of 300.47% from the latest price.

Price Target

$5.75

(300.47% upside)

Analyst Consensus: Strong Buy